-
ViiV Healthcare’s Dovato Shows Non-Inferior Efficacy and Less Weight Gain in Pivotal PASO DOBLE Study
•
ViiV Healthcare, the HIV-focused subsidiary majority-owned by GSK with Pfizer and Shionogi as shareholders, has reported positive topline results from the Phase IV PASO DOBLE study. This clinical trial compared ViiV’s two-drug regimen Dovato (dolutegravir/lamivudine) to Gilead’s three-drug regimen Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate) in the treatment of HIV-1 over a…
-
ViiV Healthcare’s HIV-PreP Therapy Approved by China’s NMPA, Offers Alternative to Daily Medication
•
GlaxoSmithKline’s (GSK; NYSE: GSK) subsidiary, ViiV Healthcare, has announced that it has received marketing approvals from China’s National Medical Products Administration (NMPA) for both cabotegravir tablets and cabotegravir injection. These medications are intended for pre-exposure prophylaxis (PrEP) of HIV-1 in adults and adolescents weighing at least 35kg who are at…
-
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy
•
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the appointment of Dr. Brian Alvin Johns as the firm’s Chief Scientific Officer (CSO), effective from January 3, 2024. In his new role, Dr. Johns will be responsible for overseeing the company’s discovery programs and charting…
